Scinai Immunotherapeutics Ltd. American Depositary Shares (SCNI) Stock Price

SCNIStock

$2.88−80.44%52W

Market Cap$1.49M

P/E0.41x

PEG Ratio—

Div yield—

Beta2.18

SCNI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-71.53%

Price vs S&P 500 (4W)15.51%

VGM Score53.73

P/E Ratio (Annual)0.41x

Book Value / Share (Quarterly)$0.00

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.00

Price vs S&P 500 (YTD)-68.00%

Gross Margin (TTM)-195.88%

Net Profit Margin (TTM)-344.50%

EPS (TTM)$-0.00

10-Day Avg Trading Volume0.10M

EPS Excl Extra (TTM)$-0.00

EPS (Annual)$-0.00

ROI (Annual)-98.93%

Gross Margin (Annual)-202.29%

Cash / Share (Quarterly)$0.00

P/E Basic Excl Extra (TTM)0.48x

Revenue Growth QoQ (YoY)536.41%

P/E Normalized (Annual)0.41x

ROA (Last FY)-71.45%

Revenue Growth TTM (YoY)216.72%

EBITD / Share (TTM)$-0.00

ROE (5Y Avg)-62.91%

Operating Margin (TTM)-296.00%

Cash Flow / Share (Annual)$-0.00

P/B Ratio15.17x

P/B Ratio (Quarterly)0.17x

Net Income / Employee (Annual)$-184,600

EV / Revenue (TTM)68.30x

Net Interest Coverage (TTM)-9.86x

ROA (TTM)-64.77%

EV / EBITDA (TTM)22.00x

EPS Incl Extra (Annual)$-0.00

Current Ratio (Annual)1.30x

Quick Ratio (Quarterly)1.22x

3-Month Avg Trading Volume0.28M

52-Week Price Return-80.44%

P/E Incl Extra (TTM)0.48x

Revenue / Employee (TTM)$57,200

Tangible BV / Share (Quarterly)$-1.96

P/S Ratio (Annual)136.09x

Asset Turnover (Annual)0.11x

52-Week High$17.20

EPS Excl Extra (Annual)$-0.00

CapEx CAGR (5Y)-57.75%

26-Week Price Return-60.28%

Quick Ratio (Annual)1.25x

13-Week Price Return-37.02%

Total Debt / Equity (Annual)0.04x

Current Ratio (Quarterly)1.35x

Enterprise Value$175.74M

Asset Turnover (TTM)0.19x

Revenue / Employee (Annual)$29,100

Pretax Margin (Annual)-633.64%

Cash / Share (Annual)$0.00

3-Month Return Std Dev89.91%

Net Income / Employee (TTM)$-197,000

ROE (Last FY)-102.52%

Net Interest Coverage (Annual)-6.10x

EPS Basic Excl Extra (Annual)$-0.00

Receivables Turnover (TTM)26.72x

Total Debt / Equity (Quarterly)0.02x

EPS Incl Extra (TTM)$-0.00

ROI (TTM)-92.99%

P/S Ratio (TTM)69.34x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$-0.71

Price vs S&P 500 (52W)-98.75%

P/E Ratio (TTM)0.48x

Year-to-Date Return-56.04%

5-Day Price Return33.19%

EPS Normalized (Annual)$-0.00

ROA (5Y Avg)-26.60%

Net Profit Margin (Annual)-633.64%

Month-to-Date Return14.65%

EBITD / Share (Annual)$-0.00

Operating Margin (Annual)-575.29%

LT Debt / Equity (Annual)0.04x

ROI (5Y Avg)-37.83%

P/E Excl Extra (TTM)0.48x

LT Debt / Equity (Quarterly)0.02x

EPS Basic Excl Extra (TTM)$-0.00

P/B Ratio (Annual)0.08x

Pretax Margin (TTM)-344.50%

Book Value / Share (Annual)$0.00

Price vs S&P 500 (13W)-39.82%

Beta2.18x

Revenue / Share (TTM)$0.00

ROE (TTM)-95.92%

52-Week Low$2.15

vGradeC

gGradeA

mGradeD

vgmGradeC

SCNI Earnings Surprise History

Q1 23-120.00est. -73.00

Q2 23-120.00est. -91.00

Q3 2380.00est. -94.00

Q4 23-240.00est. -62.00

SCNI Analyst Recommendations

May 2024

Jun 2024

Jul 2024

Aug 2024

4.14

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
SCNIScinai Immunotherapeutics Ltd. American Depositary Shares	C	A	D	$2.88
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Scinai Immunotherapeutics Ltd. American Depositary Shares

Scinai Immunotherapeutics operates a diversified biopharmaceutical model combining contract manufacturing services with proprietary drug development. The company's CDMO division provides drug development and GMP manufacturing support to biotech clients, representing the majority of current revenue. In-house, it is developing NanoAbs—nanosized VHH antibodies—targeting inflammation and immunology conditions with significant unmet medical needs.